Wang Guo-qing, Wang Yong-sheng, Wang Rui, Wu Yang, Du Xiao-bo, Xu Jian-Rong, Diao Peng
State Key Laboratory of Biotherapy, Cancer center, West China Hospital, Sichuan University, Chengdu 610041, China.
Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 May;37(3):344-8.
To explore the feasibility of generating beta defensin 2 fusion vaccine to break the immune tolerance of self antigens associated with angiogenesis.
PCR amplification of mature beta defensin 2 (Def) and extracelluar segment of Vascular Endothelial Cadherin (Cad) was conducted. (GGGS)3 was used as linker peptide for fusion plasmid(Def-Cad). All the three segments were inserted into pSecTag2B plasmid (pSec), and CT26 tumor cells were transfected. Expression was verified by RT-PCR and chemotaxis assay. The alginate bead model was used to study the antiangiogenic effect of fusion plasmid vaccination.
All constructions were verified by sequencing and were found expressed in mammalian cell. The beta defensin 2 fusion protein had similar capacity to chemoattract dendritic cells as compared with nonfusion protein (P>0.05). The alginate bead assay revealed that the tumor-induced angiogenesis in fusion plasmid immunized mice was significantly suppressed when compared with that in nonfusion plasmid (P<0.01).
An active immunization strategy based on beta defensin 2 fused with angiogenesis related antigen of endothelial can inhibit angiogenesis and may be a useful approach for cancer therapy.
